First-Line Erlotinib Followed by Second-Line Cisplatin-Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized TrialCesare Gridelli, Francesco Perrone, Charles Butts et al.|Journal of Clinical Oncology|2012Cited by 234
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung CancerMassimo Di Maïo, Cesare Gridelli, Natasha B. Leighl et al.|Journal of Thoracic Oncology|2012Cited by 26